We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PetMed (PETS) Optimistic About New Orders Amid Cost Woes
Read MoreHide Full Article
On Jun 11, we issued an updated research report on PetMedExpress, Inc. (PETS - Free Report) . The stock carries a Zacks Rank #2 (Buy). The company is striving to implement several strategies to revitalize its top line. These include increased focus on advertising efficiency to boost new order sales and shifting sales to higher margin items while also expanding the product line.
After several quarters of drag in new order sales, we are impressed with PetMed’s improved performance through fiscal 2018. The entire year demonstrated a bullish momentum with new order sales growth of 8%, primarily on aggressive advertising. Although the company witnessed 5% softness in New Order sales during the fourth quarter, it is strategically increasing advertisements to handle the situation tactfully.
Further, reorder sales grew 10.3% in the year. In the final quarter, driven by a change in product mix to higher priced items and augmented doses, average order size rose to $89 from $86 a year ago.
PetMed is also working on improving its campaigns’ effectiveness. The company has been quite successful in pushing up its sales via the Internet. Approximately, 85% of the company’s orders was generated on the website during the fourth quarter compared with 83% in the year-ago period.
Of late, the company has started focusing on advertising abilities to better new order sales and shifting sales to higher margin items including generics while expanding its product offerings. PetMed offers a wide range of products for dogs, cats and horses. We believe that with progress in economic conditions, PetMed's broad product portfolio will help drive growth in the coming quarters.
However, with an aim to increase the recognition of its brand names, PetMed markets its products through national advertising campaigns. Under this procedure, the company has been incurring huge expenses related to advertising campaigns in the recent times. Hence, escalating advertising expenses exert pressure on the bottom line. Also, a tough competitive landscape is a major concern.
Stock Performance
Over the past three months, PetMed has underperformed its industry. The stock has declined 7.1% against the 6% growth of the industry.
Other Key Picks
Other top-ranked stocks in the broader medical sector include Abiomed, Inc. , Genomic Health, Inc. and Stryker Corporation (SYK - Free Report) .
Genomic Health has an expected growth rate of 187.5% and a Zacks Rank of 1.
Stryker has a projected long-term earnings growth rate of 9.8%. The stock carries a Zacks Rank #2 (Buy).
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
PetMed (PETS) Optimistic About New Orders Amid Cost Woes
On Jun 11, we issued an updated research report on PetMedExpress, Inc. (PETS - Free Report) . The stock carries a Zacks Rank #2 (Buy). The company is striving to implement several strategies to revitalize its top line. These include increased focus on advertising efficiency to boost new order sales and shifting sales to higher margin items while also expanding the product line.
After several quarters of drag in new order sales, we are impressed with PetMed’s improved performance through fiscal 2018. The entire year demonstrated a bullish momentum with new order sales growth of 8%, primarily on aggressive advertising. Although the company witnessed 5% softness in New Order sales during the fourth quarter, it is strategically increasing advertisements to handle the situation tactfully.
Further, reorder sales grew 10.3% in the year. In the final quarter, driven by a change in product mix to higher priced items and augmented doses, average order size rose to $89 from $86 a year ago.
PetMed is also working on improving its campaigns’ effectiveness. The company has been quite successful in pushing up its sales via the Internet. Approximately, 85% of the company’s orders was generated on the website during the fourth quarter compared with 83% in the year-ago period.
Of late, the company has started focusing on advertising abilities to better new order sales and shifting sales to higher margin items including generics while expanding its product offerings. PetMed offers a wide range of products for dogs, cats and horses. We believe that with progress in economic conditions, PetMed's broad product portfolio will help drive growth in the coming quarters.
However, with an aim to increase the recognition of its brand names, PetMed markets its products through national advertising campaigns. Under this procedure, the company has been incurring huge expenses related to advertising campaigns in the recent times. Hence, escalating advertising expenses exert pressure on the bottom line. Also, a tough competitive landscape is a major concern.
Stock Performance
Over the past three months, PetMed has underperformed its industry. The stock has declined 7.1% against the 6% growth of the industry.
Other Key Picks
Other top-ranked stocks in the broader medical sector include Abiomed, Inc. , Genomic Health, Inc. and Stryker Corporation (SYK - Free Report) .
Abiomed has a long-term growth rate of 27%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Genomic Health has an expected growth rate of 187.5% and a Zacks Rank of 1.
Stryker has a projected long-term earnings growth rate of 9.8%. The stock carries a Zacks Rank #2 (Buy).
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>